Skip to main content
Top
Published in: Hepatology International 1/2022

01-02-2022 | Stroke | Editorial

Non-alcoholic fatty liver disease in cerebrovascular disease: a bystander or a real risk factor?

Authors: Lung-Yi Mak, James Fung

Published in: Hepatology International | Issue 1/2022

Login to get access

Excerpt

Over the past decade, non-alcoholic fatty liver disease (NAFLD) has emerged to become one of the most common causes of decompensated cirrhosis, and the leading primary liver disease etiology for liver transplantation. Although NAFLD is a well-established risk factor for cardiovascular disease, its association with cerebrovascular disease is less conclusive. Furthermore, the risk factors that are associated with the development of NAFLD, including obesity, diabetes mellitus, hyperlipidemia, and hypertension, are similar to those that increase the risk of cerebrovascular events. Although the association between NAFLD and cerebrovascular events has been reported, whether NAFLD is a true independent risk factor for strokes or a mere consequence of the shared metabolic risk factors remains to be determined. …
Literature
1.
go back to reference Hu J, Xu Y, He Z, Zhang H, Lian X, Zhu T, et al. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget 2018;9:2752–2760CrossRef Hu J, Xu Y, He Z, Zhang H, Lian X, Zhu T, et al. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget 2018;9:2752–2760CrossRef
2.
go back to reference Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ 2019;367:l5367CrossRef Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ 2019;367:l5367CrossRef
3.
go back to reference Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579–1584CrossRef Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579–1584CrossRef
4.
go back to reference Domanski JP, Park SJ, Harrison SA. Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter? J Clin Gastroenterol 2012;46:427–430CrossRef Domanski JP, Park SJ, Harrison SA. Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter? J Clin Gastroenterol 2012;46:427–430CrossRef
5.
go back to reference Pickhardt PJ, Hahn L, MunozdelRio A, Park SH, Reeder SB, Said A. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. AJR Am J Roentgenol 2014;202:752–758 Pickhardt PJ, Hahn L, MunozdelRio A, Park SH, Reeder SB, Said A. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. AJR Am J Roentgenol 2014;202:752–758
6.
go back to reference El Azeem HA, el Khalek SA, El-Akabawy H, Naeim H, Khalik HA, Alfifi AA. Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc 2013;25:239–246CrossRef El Azeem HA, el Khalek SA, El-Akabawy H, Naeim H, Khalik HA, Alfifi AA. Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc 2013;25:239–246CrossRef
7.
go back to reference Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 2016;246:208–213CrossRef Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 2016;246:208–213CrossRef
8.
go back to reference Baik M, Kim SU, Kang S, Park HJ, Nam HS, Heo JH, et al. Liver fibrosis, not steatosis, associates with long-term outcomes in ischaemic stroke patients. Cerebrovasc Dis 2019;47:32–39CrossRef Baik M, Kim SU, Kang S, Park HJ, Nam HS, Heo JH, et al. Liver fibrosis, not steatosis, associates with long-term outcomes in ischaemic stroke patients. Cerebrovasc Dis 2019;47:32–39CrossRef
9.
go back to reference Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012;57:196–203CrossRef Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012;57:196–203CrossRef
10.
go back to reference Jaruvongvanich V, Chenbhanich J, Sanguankeo A, Rattanawong P, Wijarnpreecha K, Upala S. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:e28–e35CrossRef Jaruvongvanich V, Chenbhanich J, Sanguankeo A, Rattanawong P, Wijarnpreecha K, Upala S. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:e28–e35CrossRef
11.
go back to reference Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol 2014;61:148–154CrossRef Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol 2014;61:148–154CrossRef
12.
go back to reference Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietilainen KH, et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int 2011;31:176–183CrossRef Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietilainen KH, et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int 2011;31:176–183CrossRef
13.
go back to reference DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis 2013;227:429–436CrossRef DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis 2013;227:429–436CrossRef
14.
go back to reference Lombardi R, Fargion S, Fracanzani AL. Brain involvement in non-alcoholic fatty liver disease (NAFLD): a systematic review. Dig Liver Dis 2019;51:1214–1222CrossRef Lombardi R, Fargion S, Fracanzani AL. Brain involvement in non-alcoholic fatty liver disease (NAFLD): a systematic review. Dig Liver Dis 2019;51:1214–1222CrossRef
15.
go back to reference Mori T, Yoshioka K, Tanno Y, Kasakura S. Association of serum fatty acids at admission with the age of onset of intracerebral hemorrhage. Nutrients 2020;12:31 Mori T, Yoshioka K, Tanno Y, Kasakura S. Association of serum fatty acids at admission with the age of onset of intracerebral hemorrhage. Nutrients 2020;12:31
16.
go back to reference Mori T, Yoshioka K, Tanno Y, Kasakura S. Association of serum fatty acids at admission with the age of onset of acute ischemic stroke. Nutrients 2020;12:65 Mori T, Yoshioka K, Tanno Y, Kasakura S. Association of serum fatty acids at admission with the age of onset of acute ischemic stroke. Nutrients 2020;12:65
17.
go back to reference Fan YY, Chapkin RS. Importance of dietary gamma-linolenic acid in human health and nutrition. J Nutr 1998;128:1411–1414CrossRef Fan YY, Chapkin RS. Importance of dietary gamma-linolenic acid in human health and nutrition. J Nutr 1998;128:1411–1414CrossRef
18.
go back to reference Yaemsiri S, Sen S, Tinker LF, Robinson WR, Evans RW, Rosamond W, et al. Serum fatty acids and incidence of ischemic stroke among postmenopausal women. Stroke 2013;44:2710–2717CrossRef Yaemsiri S, Sen S, Tinker LF, Robinson WR, Evans RW, Rosamond W, et al. Serum fatty acids and incidence of ischemic stroke among postmenopausal women. Stroke 2013;44:2710–2717CrossRef
19.
go back to reference Li H, Hu B, Wei L, Zhou L, Zhang L, Lin Y, et al. Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions. Eur J Neurol 2018;25:577-e534CrossRef Li H, Hu B, Wei L, Zhou L, Zhang L, Lin Y, et al. Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions. Eur J Neurol 2018;25:577-e534CrossRef
20.
go back to reference Baik M, Kim SU, Nam HS, Heo JH, Kim YD. The paradoxical protective effect of liver steatosis on severity and functional outcome of ischemic stroke. Front Neurol 2019;10:375CrossRef Baik M, Kim SU, Nam HS, Heo JH, Kim YD. The paradoxical protective effect of liver steatosis on severity and functional outcome of ischemic stroke. Front Neurol 2019;10:375CrossRef
21.
go back to reference Baik M, Nam HS, Heo JH, Park HJ, Kim BK, Park JY, et al. Advanced liver fibrosis predicts unfavorable long-term prognosis in first-ever ischemic stroke or transient ischemic attack. Cerebrovasc Dis 2020;49:474–480CrossRef Baik M, Nam HS, Heo JH, Park HJ, Kim BK, Park JY, et al. Advanced liver fibrosis predicts unfavorable long-term prognosis in first-ever ischemic stroke or transient ischemic attack. Cerebrovasc Dis 2020;49:474–480CrossRef
Metadata
Title
Non-alcoholic fatty liver disease in cerebrovascular disease: a bystander or a real risk factor?
Authors
Lung-Yi Mak
James Fung
Publication date
01-02-2022
Publisher
Springer India
Published in
Hepatology International / Issue 1/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10273-9

Other articles of this Issue 1/2022

Hepatology International 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.